Ethical considerations raised by the approval of interferon beta-1b for the treatment of multiple sclerosis.
Goodkin
D E
DE
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH.
Kanoti
G A
GA
D001675:Bioethics; D030881:Disclosure; D017277:Drug Approval; D026689:Ethical Analysis; D035082:Federal Government; D033161:Government Regulation; D017408:Guidelines as Topic; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009103:Multiple Sclerosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D035842:Research Subjects; D018570:Risk Assessment; D036302:Therapeutic Human Experimentation; D014481:United States; D028761:Withholding Treatment
D016899:Interferon-beta